Long-term outcomes of graves disease in children treated with anti-thyroid drugs.

[1]  Z. Aycan,et al.  Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves’ disease: a single-center experience , 2019, Journal of pediatric endocrinology & metabolism : JPEM.

[2]  S. Pearce,et al.  2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism , 2018, European Thyroid Journal.

[3]  M. Oliveira,et al.  Treatment of Graves' disease in children: The Portuguese experience. , 2018, Endocrinologia, diabetes y nutricion.

[4]  T. Cheetham,et al.  Graves’ disease. Time to move on , 2018, Archives of Disease in Childhood.

[5]  S. McGowan,et al.  Long-term outcome of thyrotoxicosis in childhood and adolescence in the west of Scotland: the case for long-term antithyroid treatment and the importance of initial counselling , 2017, Archives of Disease in Childhood.

[6]  J. Carel,et al.  MANAGEMENT OF ENDOCRINE DISEASE: Arguments for the prolonged use of antithyroid drugs in children with Graves' disease. , 2017, European journal of endocrinology.

[7]  Hirokazu Sato,et al.  Guidelines for the treatment of childhood-onset Graves’ disease in Japan, 2016 , 2017, Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology.

[8]  P. White,et al.  Graves' disease in children: long‐term outcomes of medical therapy , 2016, Clinical endocrinology.

[9]  S. Rivkees,et al.  2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. , 2016, Thyroid : official journal of the American Thyroid Association.

[10]  Rikke Havgaard Kjær,et al.  Increasing Incidence of Juvenile Thyrotoxicosis in Denmark: A Nationwide Study, 1998-2012 , 2015, Hormone Research in Paediatrics.

[11]  M. Zacharin,et al.  Long-term outcomes of pediatric Graves’ disease , 2014, Journal of Pediatric Endocrinology & Metabolism (JPEM).

[12]  A. Pistorio,et al.  Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers. , 2014, The Journal of pediatrics.

[13]  J. Carel,et al.  Graves' disease in children. , 2014, Best practice & research. Clinical endocrinology & metabolism.

[14]  ItoKoichi,et al.  Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution. , 2014 .

[15]  M. Segni,et al.  Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves' disease-a multicenter study. , 2014, The Journal of clinical endocrinology and metabolism.

[16]  N. Mickuvienė,et al.  Independent pretreatment predictors of Graves' disease outcome. , 2013, Medicina.

[17]  J. Carel,et al.  Hyperthyroidism in Childhood: Causes, When and How to Treat , 2012, Journal of clinical research in pediatric endocrinology.

[18]  M. Benmerad,et al.  Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study. , 2012, The Journal of clinical endocrinology and metabolism.

[19]  F. Karlsson,et al.  Incidence of hyperthyroidism in Sweden. , 2011, European journal of endocrinology.

[20]  S. Rivkees.  Pediatric Graves’ Disease: Controversies in Management , 2010, Hormone Research in Paediatrics.

[21]  Mei-Hwei Chang,et al.  New growth charts for Taiwanese children and adolescents based on World Health Organization standards and health-related physical fitness. , 2010, Pediatrics and neonatology.

[22]  J. Carel,et al.  Graves’ Disease in Childhood: Advances in Management with Antithyroid Drug Therapy , 2009, Hormone Research in Paediatrics.

[23]  P. Czernichow,et al.  Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. , 2008, The Journal of clinical endocrinology and metabolism.

[24]  D. Styne,et al.  Predicting the Likelihood of Remission in Children With Graves’ Disease: A Prospective, Multicenter Study , 2008, Pediatrics.

[25]  J. Franklyn,et al.  Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. , 2006, The Journal of clinical endocrinology and metabolism.

[26]  A. Weetman.  Graves' hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission? , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[27]  N. Matsuura,et al.  Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease. , 2005, Endocrine journal.

[28]  A. Avenell,et al.  A systematic review of drug therapy for Graves' hyperthyroidism. , 2005, European journal of endocrinology.

[29]  C. Chi,et al.  Outcome of antithyroid medication and radioiodine therapy in pediatric Graves' disease. , 2003, Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi.

[30]  M. Phillip,et al.  Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. , 2000, The Journal of clinical endocrinology and metabolism.

[31]  D. Shulman,et al.  Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. , 1997, Thyroid : official journal of the American Thyroid Association.

[32]  A. Pinchera,et al.  Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. , 1997, Thyroid : official journal of the American Thyroid Association.

[33]  A. Weetman,et al.  Association of HLA‐DQA1*0501 with Graves’ disease in English Caucasian men and women , 1996, Clinical endocrinology.

[34]  H. Perrild,et al.  Incidence of juvenile thyrotoxicosis in Denmark, 1982-1988. A nationwide study. , 1994, European journal of endocrinology.

[35]  E. Landaw,et al.  Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. , 1987, The Journal of clinical endocrinology and metabolism.